Minnow Medical Names Raymond W. Cohen as Chief Executive Officer
LAGUNA HILLS, Calif., Sept. 30 /PRNewswire/ -- Minnow Medical, Inc., a developer of a novel platform technology employing radiofrequency thermoplasty for the treatment of in-stent restenosis and other peripheral vascular conditions, announced today that veteran medical technology executive Raymond W. Cohen has been named chief executive officer and a member of the board of directors.
Cohen, 51, has more than 25 years of leadership and entrepreneurial experience in health care. For the past four years, he has been the CEO of CardioPolymers, Inc., a privately-held developer of novel biotherapeutics for the treatment of congestive heart failure, which recently merged with LoneStar Heart, Inc., where Cohen remains a member of the board of directors. In 2008, during his tenure at CardioPolymers, Inc., Cohen was named by AeA (now TechAmerica) as the Private Company Life Science CEO of the Year.
Cohen serves as a member of the board of directors of publicly-traded Cardiogenesis, Inc., a manufacturer of transmyocardial revascularization lasers; publicly-traded BioLife Solutions, Inc., a manufacturer of cryopreservation products used for human cell and tissue preservation; and Syncroness, Inc., a privately-held contract engineering and product development firm; and also serves as an advisor to Fjord Ventures, LLC, a life science incubator.
Previously, Cohen served as chairman and chief executive officer of publicly-held Cardiac Science, Inc., a leading U.S. manufacturer of life-saving automatic public-access defibrillators. In 2004, Cardiac Science was ranked the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. During his tenure, Cohen was named Entrepreneur of the Year in 2002 by the Orange County Business Journal.
Cohen is a member of a number of local Southern California organizations, notably the Forum of Corporate Directors and OCTANe, where he is a member of the Biomedical Leadership Council. He is an Advisory Council member to the Keck Graduate Institute, BioScience MBA program. Cohen holds a B.S. in Business Management from Binghamton University and is an accredited public company director.
About Minnow Medical, Inc.
Minnow Medical, founded in 2003, is a privately-held, venture-backed development stage company developing novel radiofrequency (RF) thermoplasty technology directed toward patients with peripheral vascular disease. The Company is ISO 13485 Compliant and FDA registered.
Minnow's initial product, the ZCath System, combines a patented low-pressure percutaneous transluminal angioplasty balloon catheter combined with uniformed and controlled RF energy intended to safely reverse and prevent the progression of peripheral vascular disease by restoring blood flow, reducing plaque burden and reducing restenosis without vessel trauma. The product has advanced from pre-clinical to clinical stage testing and has achieved CE Mark for use in reducing plaque in peripheral leg arteries. The Company has also filed a 510(k) with the Food and Drug Administration seeking marketing clearance in the United States for the aforementioned clinical indication.
For more information on Minnow Medical, please visit the Company's website at www.minnowmedical.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at matt@allencaron.com
SOURCE Minnow Medical, Inc.